Men O O O O
With O O O O
Localized O O O O
Prostate O O O O
Cancer O O O O
Prior O O O O
to O O O O
Radical O O O O
Prostatectomy O O O O
a O O O O
study O O O O
on O O O O
[Prostate O O O O
Cancer](../prostate-cancer) O O O O
Summary Reason 5 O O
- Reason 5 O O
Eligibility Reason 5 O O
- Reason 5 O O
for Reason 5 O O
males Reason 5 O O
ages Reason 5 O O
18 Reason 5 O O
years Reason 5 O O
and Reason 5 O O
up Reason 5 O O
( Reason 5 O O
[full Reason 5 O O
criteria](#eligibility)) Reason 5 O O
- Reason 5 O O
Location Reason 5 O O
- Reason 5 O O
[at Reason 5 O O
San Reason 5 O O
Francisco, Reason 5 O O
California Reason 5 O O
and Reason 5 O O
other Reason 5 O O
locations](#location) Reason 5 O O
- Reason 5 O O
Dates Reason 5 O O
- Reason 5 O O
study Reason 5 O O
startedestimated Reason 5 O O
completion Reason 5 O O
- Reason 5 O O
Principal Reason 5 O O
Investigator Reason 5 O O
- Reason 5 O O
by Reason 5 O O
[Lawrence Reason 5 O O
Fong](https://profiles.ucsf.edu/lawrence.fong) Reason 5 O O
Description Reason 5 O O
Summary Reason 5 O O
This Reason 5 O O
phase Reason 5 O O
II Reason 5 O O
trial Reason 5 O O
studies Reason 5 O O
how Reason 5 O O
well Reason 5 O O
atezolizumab Reason 5 O O
works Reason 5 O O
alone Reason 5 O O
or Reason 5 O O
in Reason 5 O O
combination Reason 5 O O
with Reason 5 O O
etrumadenant Reason 5 O O
or Reason 5 O O
tocilizumab Reason 5 O O
in Reason 5 O O
treating Reason 5 O O
men Reason 5 O O
with Reason 5 O O
[localized Reason 5 O O
prostate Reason 5 O O
cancer](../prostate-cancer) Reason 5 O O
radical Reason 5 O O
prostatectomy. Reason 5 O O
[Immunotherapy](../immunotherapy) Reason 5 O O
with Reason 5 O O
[monoclonal Reason 5 O O
antibodies](../monoclonal-antibody), Reason 5 O O
such Reason 5 O O
as Reason 5 O O
atezolizumab, Reason 5 O O
may Reason 5 O O
help Reason 5 O O
the Reason 5 O O
body's Reason 5 O O
immune Reason 5 O O
system Reason 5 O O
attack Reason 5 O O
the Reason 5 O O
cancer, Reason 5 O O
and Reason 5 O O
may Reason 5 O O
interfere Reason 5 O O
with Reason 5 O O
the Reason 5 O O
ability Reason 5 O O
of Reason 5 O O
tumor Reason 5 O O
cells Reason 5 O O
to Reason 5 O O
grow Reason 5 O O
and Reason 5 O O
spread. Reason 5 O O
Androgens Reason 5 O O
can Reason 5 O O
cause Reason 5 O O
the Reason 5 O O
growth Reason 5 O O
of Reason 5 O O
prostate Reason 5 O O
cancer Reason 5 O O
cells. Reason 5 O O
IL-6 Reason 5 O O
is Reason 5 O O
expressed Reason 5 O O
by Reason 5 O O
prostate Reason 5 O O
cancer Reason 5 O O
and Reason 5 O O
within Reason 5 O O
the Reason 5 O O
tumor Reason 5 O O
microenvironment Reason 5 O O
and Reason 5 O O
shown Reason 5 O O
to Reason 5 O O
enhance Reason 5 O O
prostate Reason 5 O O
cancer Reason 5 O O
and Reason 5 O O
disease Reason 5 O O
progression. Reason 5 O O
Treatment Reason 5 O O
with Reason 5 O O
an Reason 5 O O
anti-IL-6 Reason 5 O O
antibody Reason 5 O O
such Reason 5 O O
as Reason 5 O O
tocilizumab Reason 5 O O
may Reason 5 O O
inhibit Reason 5 O O
cancer Reason 5 O O
progression. Reason 5 O O
Giving Reason 5 O O
atezolizumab Reason 5 O O
in Reason 5 O O
combination Reason 5 O O
with Reason 5 O O
etrumadenant Reason 5 O O
or Reason 5 O O
tocilizumab Reason 5 O O
may Reason 5 O O
work Reason 5 O O
better Reason 5 O O
in Reason 5 O O
treating Reason 5 O O
prostate Reason 5 O O
cancer. Reason 5 O O
Official Reason 5 O O
Title Reason 5 O O
An Reason 5 O O
Open-Label Reason 5 O O
Multi-Center Reason 5 O O
Phase Reason 5 O O
II Reason 5 O O
Study Reason 5 O O
of Reason 5 O O
Neoadjuvant Reason 5 O O
Atezolizumab-Based Reason 5 O O
Combination Reason 5 O O
Therapy Reason 5 O O
in Reason 5 O O
Men Reason 5 O O
With Reason 5 O O
Localized Reason 5 O O
Prostate Reason 5 O O
Cancer Reason 5 O O
Prior Reason 5 O O
to Reason 5 O O
Radical Reason 5 O O
Prostatectomy Reason 5 O O
Details Reason 5 O O
PRIMARY Reason 5 O O
OBJECTIVES: Reason 5 O O
- Reason 5 O O
To Reason 5 O O
determine Reason 5 O O
the Reason 5 O O
impact Reason 5 O O
of Reason 5 O O
atezolizumab-based Reason 5 O O
combination Reason 5 O O
therapy Reason 5 O O
on Reason 5 O O
the Reason 5 O O
composition Reason 5 O O
and Reason 5 O O
function Reason 5 O O
of Reason 5 O O
tumor-infiltrating Reason 5 O O
immune Reason 5 O O
cells Reason 5 O O
(TIICS). Reason 5 O O
SECONDARY Reason 5 O O
OBJECTIVES: Reason 5 O O
- Reason 5 O O
To Reason 5 O O
determine Reason 5 O O
the Reason 5 O O
safety Reason 5 O O
and Reason 5 O O
tolerability Reason 5 O O
of Reason 5 O O
atezolizumab-based Reason 5 O O
combination Reason 5 O O
therapy Reason 5 O O
in Reason 5 O O
[localized Reason 5 O O
prostate Reason 5 O O
cancer](../prostate-cancer)(PC). Reason 5 O O
II. Reason 5 O O
To Reason 5 O O
determine Reason 5 O O
the Reason 5 O O
clinical Reason 5 O O
efficacy Reason 5 O O
of Reason 5 O O
atezolizumab-based Reason 5 O O
combination Reason 5 O O
therapy Reason 5 O O
in Reason 5 O O
localized Reason 5 O O
PC. Reason 5 O O
EXPLORATORY Reason 5 O O
OBJECTIVES: Reason 5 O O
- Reason 5 O O
To Reason 5 O O
characterize Reason 5 O O
changes Reason 5 O O
in Reason 5 O O
the Reason 5 O O
frequency Reason 5 O O
and Reason 5 O O
number Reason 5 O O
of Reason 5 O O
circulating Reason 5 O O
immune Reason 5 O O
cells Reason 5 O O
following Reason 5 O O
atezolizumab-based Reason 5 O O
combination Reason 5 O O
therapy Reason 5 O O
in Reason 5 O O
localized Reason 5 O O
PC. Reason 5 O O
II. Reason 5 O O
To Reason 5 O O
determine Reason 5 O O
the Reason 5 O O
impact Reason 5 O O
of Reason 5 O O
atezolizumab-based Reason 5 O O
combination Reason 5 O O
therapy Reason 5 O O
on Reason 5 O O
the Reason 5 O O
composition Reason 5 O O
and Reason 5 O O
phenotype Reason 5 O O
of Reason 5 O O
the Reason 5 O O
tumor Reason 5 O O
microenvironment. Reason 5 O O
III. Reason 5 O O
To Reason 5 O O
determine Reason 5 O O
the Reason 5 O O
impact Reason 5 O O
of Reason 5 O O
atezolizumab-based Reason 5 O O
combination Reason 5 O O
therapy Reason 5 O O
on Reason 5 O O
the Reason 5 O O
circulating Reason 5 O O
and Reason 5 O O
intratumoral Reason 5 O O
T Reason 5 O O
cell Reason 5 O O
repertoire. Reason 5 O O
IV. Reason 5 O O
To Reason 5 O O
explore Reason 5 O O
the Reason 5 O O
role Reason 5 O O
of Reason 5 O O
novel Reason 5 O O
imaging Reason 5 O O
modalities Reason 5 O O
to Reason 5 O O
understand Reason 5 O O
the Reason 5 O O
immunologic Reason 5 O O
and Reason 5 O O
clinical Reason 5 O O
impact Reason 5 O O
to Reason 5 O O
immunotherapeutic Reason 5 O O
approaches Reason 5 O O
in Reason 5 O O
localized Reason 5 O O
PC. Reason 5 O O
- Reason 5 O O
To Reason 5 O O
characterize Reason 5 O O
changes Reason 5 O O
in Reason 5 O O
the Reason 5 O O
[gut Reason 5 O O
microbiome](../gut-microbiome)associated Reason 5 O O
with Reason 5 O O
each Reason 5 O O
therapeutic Reason 5 O O
combination. Reason 5 O O
OUTLINE: Reason 5 O O
Patients Reason 5 O O
are Reason 5 O O
assigned Reason 5 O O
sequentially Reason 5 O O
to Reason 5 O O
1 Reason 5 O O
of Reason 5 O O
2 Reason 5 O O
groups. Reason 5 O O
COHORT Reason 5 O O
A: Reason 5 O O
Patients Reason 5 O O
receive Reason 5 O O
one Reason 5 O O
cycle Reason 5 O O
of Reason 5 O O
atezolizumab Reason 5 O O
intravenously Reason 5 O O
(IV) Reason 5 O O
over Reason 5 O O
30-60 Reason 5 O O
minutes Reason 5 O O
on Reason 5 O O
day Reason 5 O O
1 Reason 5 O O
of Reason 5 O O
a Reason 5 O O
14 Reason 5 O O
day Reason 5 O O
cycle Reason 5 O O
prior Reason 5 O O
to Reason 5 O O
radical Reason 5 O O
prostatectomy Reason 5 O O
(RP). Reason 5 O O
COHORT Reason 5 O O
B: Reason 5 O O
Patients Reason 5 O O
will Reason 5 O O
receive Reason 5 O O
1 Reason 5 O O
cycle Reason 5 O O
of Reason 5 O O
neoadjuvant Reason 5 O O
atezolizumab Reason 5 O O
and Reason 5 O O
etrumadenant Reason 5 O O
(AB928) Reason 5 O O
prior Reason 5 O O
to Reason 5 O O
RP; Reason 5 O O
atezolizumab Reason 5 O O
will Reason 5 O O
be Reason 5 O O
administered Reason 5 O O
in Reason 5 O O
an Reason 5 O O
identical Reason 5 O O
fashion Reason 5 O O
as Reason 5 O O
Cohort Reason 5 O O
A. Reason 5 O O
Etrumadenant Reason 5 O O
will Reason 5 O O
be Reason 5 O O
administered Reason 5 O O
at Reason 5 O O
a Reason 5 O O
dose Reason 5 O O
of Reason 5 O O
150 Reason 5 O O
mg Reason 5 O O
once Reason 5 O O
daily, Reason 5 O O
until Reason 5 O O
48 Reason 5 O O
hours Reason 5 O O
prior Reason 5 O O
to Reason 5 O O
RP. Reason 5 O O
COHORT Reason 5 O O
C: Reason 5 O O
Patients Reason 5 O O
will Reason 5 O O
receive Reason 5 O O
1 Reason 5 O O
cycle Reason 5 O O
of Reason 5 O O
neoadjuvant Reason 5 O O
atezolizumab Reason 5 O O
and Reason 5 O O
tocilizumab Reason 5 O O
prior Reason 5 O O
to Reason 5 O O
RP; Reason 5 O O
atezolizumab Reason 5 O O
will Reason 5 O O
be Reason 5 O O
administered Reason 5 O O
in Reason 5 O O
an Reason 5 O O
identical Reason 5 O O
fashion Reason 5 O O
as Reason 5 O O
Cohort Reason 5 O O
A. Reason 5 O O
Etrumadenant Reason 5 O O
will Reason 5 O O
be Reason 5 O O
administered Reason 5 O O
at Reason 5 O O
a Reason 5 O O
dose Reason 5 O O
of Reason 5 O O
6mg/kg. Reason 5 O O
Two Reason 5 O O
more Reason 5 O O
groups Reason 5 O O
consisting Reason 5 O O
of Reason 5 O O
treatment Reason 5 O O
with Reason 5 O O
atezolizumab Reason 5 O O
in Reason 5 O O
combination Reason 5 O O
with Reason 5 O O
other Reason 5 O O
drugs Reason 5 O O
may Reason 5 O O
be Reason 5 O O
added Reason 5 O O
in Reason 5 O O
the Reason 5 O O
future. Reason 5 O O
RP Reason 5 O O
will Reason 5 O O
occur Reason 5 O O
21 Reason 5 O O
days Reason 5 O O
(+/- Reason 5 O O
7 Reason 5 O O
days) Reason 5 O O
following Reason 5 O O
treatments Reason 5 O O
on Reason 5 O O
Cycle Reason 5 O O
1 Reason 5 O O
Day Reason 5 O O
1. Reason 5 O O
No Reason 5 O O
further Reason 5 O O
study Reason 5 O O
therapy Reason 5 O O
will Reason 5 O O
be Reason 5 O O
administered Reason 5 O O
following Reason 5 O O
RP Reason 5 O O
Following Reason 5 O O
RP, Reason 5 O O
subjects Reason 5 O O
will Reason 5 O O
be Reason 5 O O
followed Reason 5 O O
at Reason 5 O O
6 Reason 5 O O
weeks, Reason 5 O O
3 Reason 5 O O
months, Reason 5 O O
6 Reason 5 O O
months, Reason 5 O O
and Reason 5 O O
12 Reason 5 O O
months Reason 5 O O
(from Reason 5 O O
date Reason 5 O O
of Reason 5 O O
RP), Reason 5 O O
or Reason 5 O O
until Reason 5 O O
disease Reason 5 O O
progression, Reason 5 O O
whichever Reason 5 O O
occurs Reason 5 O O
sooner Reason 5 O O
Keywords Reason 5 O O
Prostate Reason 5 O O
Adenocarcinoma, Reason 5 O O
Prostate Reason 5 O O
Cancer, Reason 5 O O
can Reason 5 O O
join Reason 5 O O
if... Reason 5 O O
Open Reason 5 O O
to Reason 5 O O
males Reason 5 O O
ages Reason 5 O O
18 Reason 5 O O
years Reason 5 O O
and Reason 5 O O
up Reason 5 O O
- Reason 5 O O
Histologically Reason 5 O O
confirmed Reason 5 O O
[adenocarcinoma Reason 5 O O
of Reason 5 O O
the Reason 5 O O
prostate](../prostate-cancer). Reason 5 O O
- Reason 5 O O
Subjects Reason 5 O O
with Reason 5 O O
small Reason 5 O O
cell Reason 5 O O
or Reason 5 O O
neuroendocrine Reason 5 O O
PC Reason 5 O O
are Reason 5 O O
not Reason 5 O O
eligible. Reason 5 O O
- Reason 5 O O
Eligible Reason 5 O O
for Reason 5 O O
radical Reason 5 O O
prostatectomy Reason 5 O O
as Reason 5 O O
determined Reason 5 O O
by Reason 5 O O
urologic Reason 5 O O
oncology Reason 5 O O
surgeon, Reason 5 O O
and Reason 5 O O
subject Reason 5 O O
consents Reason 5 O O
to Reason 5 O O
proceeding Reason 5 O O
with Reason 5 O O
radical Reason 5 O O
prostatectomy. Reason 5 O O
- Reason 5 O O
Deemed Reason 5 O O
by Reason 5 O O
urologic Reason 5 O O
oncology Reason 5 O O
surgeon Reason 5 O O
to Reason 5 O O
be Reason 5 O O
appropriate Reason 5 O O
for Reason 5 O O
a Reason 5 O O
"window-of-opportunity"study. Reason 5 O O
- Reason 5 O O
Only Reason 5 O O
patients Reason 5 O O
with Reason 5 O O
high-risk Reason 5 O O
disease Reason 5 O O
are Reason 5 O O
eligible Reason 5 O O
for Reason 5 O O
the Reason 5 O O
safety Reason 5 O O
lead-in Reason 5 O O
for Reason 5 O O
each Reason 5 O O
cohort. Reason 5 O O
Patients Reason 5 O O
with Reason 5 O O
intermediate-risk Reason 5 O O
disease Reason 5 O O
will Reason 5 O O
be Reason 5 O O
included Reason 5 O O
after Reason 5 O O
interim Reason 5 O O
analyses Reason 5 O O
is Reason 5 O O
complete Reason 5 O O
for Reason 5 O O
the Reason 5 O O
corresponding Reason 5 O O
cohort Reason 5 O O
and Reason 5 O O
the Reason 5 O O
PI Reason 5 O O
has Reason 5 O O
determined Reason 5 O O
that Reason 5 O O
it Reason 5 O O
is Reason 5 O O
safe Reason 5 O O
to Reason 5 O O
do Reason 5 O O
so. Reason 5 O O
- Reason 5 O O
Availability Reason 5 O O
of Reason 5 O O
a Reason 5 O O
representative Reason 5 O O
tumor Reason 5 O O
specimen Reason 5 O O
that Reason 5 O O
is Reason 5 O O
suitable Reason 5 O O
for Reason 5 O O
the Reason 5 O O
planned Reason 5 O O
study Reason 5 O O
analyses, Reason 5 O O
as Reason 5 O O
determined Reason 5 O O
by Reason 5 O O
the Reason 5 O O
Principal Reason 5 O O
Investigator. Reason 5 O O
- Reason 5 O O
A Reason 5 O O
formalin-fixed Reason 5 O O
paraffin-embedded Reason 5 O O
(FFPE) Reason 5 O O
tumor Reason 5 O O
specimen Reason 5 O O
in Reason 5 O O
a Reason 5 O O
paraffin Reason 5 O O
block Reason 5 O O
(preferred) Reason 5 O O
or Reason 5 O O
at Reason 5 O O
least Reason 5 O O
15 Reason 5 O O
slides Reason 5 O O
containing Reason 5 O O
unstained, Reason 5 O O
freshly Reason 5 O O
cut, Reason 5 O O
serial Reason 5 O O
sections Reason 5 O O
should Reason 5 O O
be Reason 5 O O
submitted Reason 5 O O
along Reason 5 O O
with Reason 5 O O
an Reason 5 O O
associated Reason 5 O O
pathology Reason 5 O O
report Reason 5 O O
prior Reason 5 O O
to Reason 5 O O
study Reason 5 O O
treatment. Reason 5 O O
If Reason 5 O O
only Reason 5 O O
10-14 Reason 5 O O
slides Reason 5 O O
are Reason 5 O O
available, Reason 5 O O
the Reason 5 O O
patient Reason 5 O O
may Reason 5 O O
still Reason 5 O O
be Reason 5 O O
eligible Reason 5 O O
for Reason 5 O O
the Reason 5 O O
study, Reason 5 O O
after Reason 5 O O
Principal Reason 5 O O
Investigator Reason 5 O O
approval Reason 5 O O
has Reason 5 O O
been Reason 5 O O
obtained. Reason 5 O O
- Reason 5 O O
If Reason 5 O O
archival Reason 5 O O
tumor Reason 5 O O
tissue Reason 5 O O
is Reason 5 O O
unavailable Reason 5 O O
or Reason 5 O O
is Reason 5 O O
determined Reason 5 O O
to Reason 5 O O
be Reason 5 O O
unsuitable Reason 5 O O
for Reason 5 O O
required Reason 5 O O
testing, Reason 5 O O
tumor Reason 5 O O
tissue Reason 5 O O
must Reason 5 O O
be Reason 5 O O
obtained Reason 5 O O
from Reason 5 O O
a Reason 5 O O
biopsy Reason 5 O O
performed Reason 5 O O
at Reason 5 O O
screening. Reason 5 O O
Refer Reason 5 O O
to Reason 5 O O
Section Reason 5 O O
6.3 Reason 5 O O
for Reason 5 O O
additional Reason 5 O O
information Reason 5 O O
on Reason 5 O O
tumor Reason 5 O O
specimens Reason 5 O O
collected Reason 5 O O
at Reason 5 O O
screening. Reason 5 O O
- Reason 5 O O
Subjects Reason 5 O O
have Reason 5 O O
not Reason 5 O O
received Reason 5 O O
any Reason 5 O O
prior Reason 5 O O
systemic Reason 5 O O
or Reason 5 O O
locally Reason 5 O O
directed Reason 5 O O
therapy Reason 5 O O
for Reason 5 O O
PC Reason 5 O O
(see Reason 5 O O
You Reason 5 O O
CAN'T Reason 5 O O
join Reason 5 O O
if... Reason 5 O O
). Reason 5 O O
6. Reason 5 O O
Age Reason 5 O O
>= Reason 5 O O
18 Reason 5 O O
years Reason 5 O O
7. Reason 5 O O
Eastern Reason 5 O O
Cooperative Reason 5 O O
Oncology Reason 5 O O
Group Reason 5 O O
(ECOG) Reason 5 O O
performance Reason 5 O O
status Reason 5 O O
of Reason 5 O O
0 Reason 5 O O
or Reason 5 O O
1 Reason 5 O O
8. Reason 5 O O
Requirements Reason 5 O O
for Reason 5 O O
organ Reason 5 O O
and Reason 5 O O
marrow Reason 5 O O
function: Reason 5 O O
- Reason 5 O O
Hemoglobin Reason 5 O O
>= Reason 5 O O
9 Reason 5 O O
g/dL Reason 5 O O
- Reason 5 O O
- Reason 5 O O
Participants Reason 5 O O
must Reason 5 O O
not Reason 5 O O
have Reason 5 O O
been Reason 5 O O
transfused Reason 5 O O
within Reason 5 O O
2 Reason 5 O O
weeks Reason 5 O O
prior Reason 5 O O
to Reason 5 O O
screening Reason 5 O O
to Reason 5 O O
meet Reason 5 O O
this Reason 5 O O
criterion Reason 5 O O
- Reason 5 O O
Absolute Reason 5 O O
neutrophil Reason 5 O O
count Reason 5 O O
>= Reason 5 O O
1,500/microliter Reason 5 O O
(uL) Reason 5 O O
without Reason 5 O O
>= Reason 5 O O
500/uL Reason 5 O O
- Reason 5 O O
Platelets Reason 5 O O
>= Reason 5 O O
100,000/uL Reason 5 O O
without Reason 5 O O
transfusion Reason 5 O O
- Reason 5 O O
Total Reason 5 O O
bilirubin Reason 5 O O
< Reason 5 O O
1.5 Reason 5 O O
x Reason 5 O O
institutional Reason 5 O O
upper Reason 5 O O
limit Reason 5 O O
of Reason 5 O O
normal Reason 5 O O
(ULN) Reason 5 O O
(known Reason 5 O O
Gilbert Reason 5 O O
disease: Reason 5 O O
< Reason 5 O O
3 Reason 5 O O
x Reason 5 O O
ULN) Reason 5 O O
- Reason 5 O O
Alkaline Reason 5 O O
phosphatase Reason 5 O O
< Reason 5 O O
normalized Reason 5 O O
ratio Reason 5 O O
(INR) Reason 5 O O
or Reason 5 O O
activated Reason 5 O O
partial Reason 5 O O
thromboplastin Reason 5 O O
time Reason 5 O O
(aPTT) Reason 5 O O
< Reason 5 O O
1.5 Reason 5 O O
x Reason 5 O O
institutional Reason 5 O O
ULN Reason 5 O O
for Reason 5 O O
subjects Reason 5 O O
not Reason 5 O O
receiving Reason 5 O O
therapeutic Reason 5 O O
anticoagulation Reason 5 O O
- Reason 5 O O
Creatinine Reason 5 O O
clearance Reason 5 O O
>= Reason 5 O O
30 Reason 5 O O
mL/min Reason 5 O O
Serum Reason 5 O O
creatinine Reason 5 O O
<=1.6 Reason 5 O O
mg/dL Reason 5 O O
(141 Reason 5 O O
mol/L) Reason 5 O O
in Reason 5 O O
female Reason 5 O O
patients Reason 5 O O
and Reason 5 O O
1.9 Reason 5 O O
mg/dL Reason 5 O O
(168 Reason 5 O O
mol/L) Reason 5 O O
in Reason 5 O O
male Reason 5 O O
patients Reason 5 O O
. Reason 5 O O
Patients Reason 5 O O
with Reason 5 O O
serum Reason 5 O O
creatinine Reason 5 O O
values Reason 5 O O
exceeding Reason 5 O O
limits Reason 5 O O
may Reason 5 O O
be Reason 5 O O
eligible Reason 5 O O
for Reason 5 O O
the Reason 5 O O
study Reason 5 O O
if Reason 5 O O
their Reason 5 O O
estimated Reason 5 O O
glomerular Reason 5 O O
filtration Reason 5 O O
rates Reason 5 O O
(GFR) Reason 5 O O
are Reason 5 O O
>30 Reason 5 O O
9. Reason 5 O O
Testosterone Reason 5 O O
level Reason 5 O O
> Reason 5 O O
150 Reason 5 O O
ng/dL. Reason 5 O O
10. Reason 5 O O
Contraception: Reason 5 O O
agreement Reason 5 O O
to Reason 5 O O
remain Reason 5 O O
abstinent Reason 5 O O
or Reason 5 O O
use Reason 5 O O
contraceptive Reason 5 O O
measures, Reason 5 O O
and Reason 5 O O
agreement Reason 5 O O
to Reason 5 O O
refrain Reason 5 O O
from Reason 5 O O
donating Reason 5 O O
sperm Reason 5 O O
as Reason 5 O O
defined Reason 5 O O
below: Reason 5 O O
1. Reason 5 O O
With Reason 5 O O
female Reason 5 O O
partners Reason 5 O O
of Reason 5 O O
childbearing Reason 5 O O
potential: Reason 5 O O
men Reason 5 O O
must Reason 5 O O
remain Reason 5 O O
abstinent Reason 5 O O
or Reason 5 O O
use Reason 5 O O
a Reason 5 O O
condom Reason 5 O O
plus Reason 5 O O
an Reason 5 O O
additional Reason 5 O O
contraceptive Reason 5 O O
method Reason 5 O O
that Reason 5 O O
together Reason 5 O O
result Reason 5 O O
in Reason 5 O O
a Reason 5 O O
failure Reason 5 O O
rate Reason 5 O O
of Reason 5 O O
< Reason 5 O O
1% Reason 5 O O
per Reason 5 O O
year Reason 5 O O
during Reason 5 O O
the Reason 5 O O
treatment Reason 5 O O
period Reason 5 O O
and Reason 5 O O
for Reason 5 O O
4 Reason 5 O O
months Reason 5 O O
after Reason 5 O O
the Reason 5 O O
last Reason 5 O O
dose Reason 5 O O
of Reason 5 O O
study Reason 5 O O
treatment. Reason 5 O O
Men Reason 5 O O
must Reason 5 O O
refrain Reason 5 O O
from Reason 5 O O
donating Reason 5 O O
sperm Reason 5 O O
during Reason 5 O O
the Reason 5 O O
same Reason 5 O O
period Reason 5 O O
2. Reason 5 O O
With Reason 5 O O
pregnant Reason 5 O O
female Reason 5 O O
partners: Reason 5 O O
men Reason 5 O O
must Reason 5 O O
remain Reason 5 O O
abstinent Reason 5 O O
or Reason 5 O O
use Reason 5 O O
a Reason 5 O O
condom Reason 5 O O
during Reason 5 O O
the Reason 5 O O
treatment Reason 5 O O
period Reason 5 O O
and Reason 5 O O
for Reason 5 O O
4 Reason 5 O O
months Reason 5 O O
after Reason 5 O O
the Reason 5 O O
last Reason 5 O O
dose Reason 5 O O
of Reason 5 O O
study Reason 5 O O
treatment Reason 5 O O
to Reason 5 O O
avoid Reason 5 O O
exposing Reason 5 O O
the Reason 5 O O
embryo Reason 5 O O
3. Reason 5 O O
Abstinence: Reason 5 O O
the Reason 5 O O
reliability Reason 5 O O
of Reason 5 O O
sexual Reason 5 O O
abstinence Reason 5 O O
should Reason 5 O O
be Reason 5 O O
evaluated Reason 5 O O
in Reason 5 O O
relation Reason 5 O O
to Reason 5 O O
the Reason 5 O O
duration Reason 5 O O
of Reason 5 O O
the Reason 5 O O
clinical Reason 5 O O
trial Reason 5 O O
and Reason 5 O O
the Reason 5 O O
preferred Reason 5 O O
and Reason 5 O O
usual Reason 5 O O
lifestyle Reason 5 O O
of Reason 5 O O
the Reason 5 O O
patient. Reason 5 O O
Periodic Reason 5 O O
abstinence Reason 5 O O
(e.g., Reason 5 O O
calendar, Reason 5 O O
ovulation, Reason 5 O O
symptothermal, Reason 5 O O
or Reason 5 O O
postovulation Reason 5 O O
methods) Reason 5 O O
and Reason 5 O O
withdrawal Reason 5 O O
are Reason 5 O O
not Reason 5 O O
acceptable Reason 5 O O
methods Reason 5 O O
of Reason 5 O O
[contraception](../contraception) Reason 5 O O
11. Reason 5 O O
For Reason 5 O O
patients Reason 5 O O
receiving Reason 5 O O
therapeutic Reason 5 O O
anticoagulation: Reason 5 O O
stable Reason 5 O O
anticoagulant Reason 5 O O
regimen Reason 5 O O
> Reason 5 O O
3 Reason 5 O O
months. Reason 5 O O
12. Reason 5 O O
Ability Reason 5 O O
to Reason 5 O O
understand Reason 5 O O
a Reason 5 O O
written Reason 5 O O
informed Reason 5 O O
consent Reason 5 O O
document, Reason 5 O O
and Reason 5 O O
the Reason 5 O O
willingness Reason 5 O O
to Reason 5 O O
sign Reason 5 O O
it. Reason 5 O O
13. Reason 5 O O
Ability Reason 5 O O
to Reason 5 O O
comply Reason 5 O O
with Reason 5 O O
the Reason 5 O O
study Reason 5 O O
protocol, Reason 5 O O
in Reason 5 O O
the Reason 5 O O
investigator's Reason 5 O O
judgment. Reason 5 O O
Exclusion Reason 5 O O
Criteria: Reason 5 O O
1. Reason 1 O O
Evidence Reason 1 O O
of Reason 1 O O
metastatic Reason 1 O O
disease Reason 1 O O
as Reason 1 O O
determined Reason 1 O O
by Reason 1 O O
standard Reason 1 O O
staging Reason 1 O O
scans. Reason 1 O O
a. O O O O
Staging O O O O
scans O O O O
should O O O O
be O O O O
performed O O O O
per O O O O
urologic O O O O
standard O O O O
of O O O O
care O O O O
for O O O O
patients O O O O
undergoing O O O O
radical O O O O
prostatectomy O O O O
[per O O O O
American O O O O
Urological O O O O
Association O O O O
(AUA)/National O O O O
Comprehensive O O O O
Cancer O O O O
Network O O O O
(NCCN) O O O O
guidelines]. O O O O
2. Reason 1 O O
Not Reason 1 O O
a Reason 1 O O
candidate Reason 1 O O
for Reason 1 O O
radical Reason 1 O O
prostatectomy Reason 1 O O
as Reason 1 O O
determined Reason 1 O O
by Reason 1 O O
treating Reason 1 O O
urologic Reason 1 O O
oncology Reason 1 O O
surgeon Reason 1 O O
3. O O O O
Any O O O O
prior O O O O
systemic O O O O
therapy O O O O
for O O O O
PC, O O O O
including O O O O
antiandrogens, O O O O
[androgen O O O O
deprivation O O O O
therapy](../androgen-deprivation-therapy) O O O O
[gonadotropin-releasing O O O O
hormone O O O O
targeted O O O O
therapy, O O O O
[immunotherapy](../immunotherapy), O O O O
OR O O O O
radiopharmaceuticals. O O O O
a. Reason 1 O O
Subjects Reason 1 O O
who Reason 1 O O
are Reason 1 O O
on Reason 1 O O
finasteride Reason 1 O O
or Reason 1 O O
dutasteride Reason 1 O O
must Reason 1 O O
discontinue Reason 1 O O
therapy Reason 1 O O
and Reason 1 O O
undergo Reason 1 O O
a Reason 1 O O
washout Reason 1 O O
period Reason 1 O O
of Reason 1 O O
6 Reason 1 O O
weeks Reason 1 O O
to Reason 1 O O
become Reason 1 O O
eligible Reason 1 O O
for Reason 1 O O
the Reason 1 O O
study. Reason 1 O O
Screening O O O O
procedures O O O O
should O O O O
begin O O O O
following O O O O
the O O O O
washout O O O O
period O O O O
4. Reason 1 O O
Prior Reason 1 O O
radiotherapy Reason 1 O O
for Reason 1 O O
PC. Reason 1 O O
5. O O O O
Any O O O O
history O O O O
of O O O O
prior O O O O
malignancy, O O O O
except: O O O O
1. Reason 2 O O
Non-melanoma Reason 2 O O
skin Reason 2 O O
cancer Reason 2 O O
treated Reason 2 O O
with Reason 2 O O
curative Reason 2 O O
intent Reason 2 O O
2. O O O O
[Carcinoma-in-situ](../carcinoma-in-situ) O O O O
(CIS) O O O O
treated O O O O
with O O O O
curative O O O O
intent, O O O O
without O O O O
evidence O O O O
of O O O O
recurrence O O O O
or O O O O
disease O O O O
progression O O O O
for O O O O
3 O O O O
years O O O O
3. Reason 2 O O
Appropriately Reason 2 O O
treated Reason 2 O O
Stage Reason 2 O O
I Reason 2 O O
[uterine Reason 2 O O
cancer](../uterine-cancer) Reason 2 O O
4. O O O O
All O O O O
other O O O O
cancer: O O O O
treated O O O O
with O O O O
curative O O O O
intent O O O O
and O O O O
without O O O O
evidence O O O O
of O O O O
disease O O O O
on O O O O
standard O O O O
of O O O O
care O O O O
follow-up O O O O
for O O O O
5 O O O O
years O O O O
6. Reason 3 O O
Active Reason 3 O O
or Reason 3 O O
history Reason 3 O O
of Reason 3 O O
[autoimmune Reason 3 O O
disease](../autoimmune-disease) Reason 3 O O
or Reason 3 O O
[immune Reason 3 O O
deficiency](../immunodeficiency), Reason 3 O O
including, Reason 3 O O
but Reason 3 O O
syndrome, Reason 3 O O
or Reason 3 O O
[multiple Reason 3 O O
sclerosis](../multiple-sclerosis), Reason 3 O O
with Reason 3 O O
the Reason 3 O O
following Reason 3 O O
exceptions: Reason 3 O O
1. Reason 3 O O
Subjects Reason 3 O O
with Reason 3 O O
a Reason 3 O O
history Reason 3 O O
of Reason 3 O O
autoimmune-related Reason 3 O O
[hypothyroidism](../hypothyroidism) Reason 3 O O
who Reason 3 O O
are Reason 3 O O
on Reason 3 O O
thyroid-replacement Reason 3 O O
therapy, Reason 3 O O
with Reason 3 O O
a Reason 3 O O
stable Reason 3 O O
dose Reason 3 O O
> Reason 3 O O
3 Reason 3 O O
months, Reason 3 O O
are Reason 3 O O
eligible Reason 3 O O
for Reason 3 O O
the Reason 3 O O
study Reason 3 O O
2. Reason 3 O O
Subjects Reason 3 O O
with Reason 3 O O
controlled Reason 3 O O
[type Reason 3 O O
1 Reason 3 O O
diabetes Reason 3 O O
mellitus](../diabetes-type-1) Reason 3 O O
who Reason 3 O O
are Reason 3 O O
on Reason 3 O O
an Reason 3 O O
insulin Reason 3 O O
regimen, Reason 3 O O
with Reason 3 O O
a Reason 3 O O
Glycated Reason 3 O O
hemoglobin Reason 3 O O
(hemoglobin Reason 3 O O
A1C) Reason 3 O O
< Reason 3 O O
7.0 Reason 3 O O
are Reason 3 O O
eligible Reason 3 O O
for Reason 3 O O
the Reason 3 O O
study. Reason 3 O O
All Reason 3 O O
subjects Reason 3 O O
with Reason 3 O O
controlled Reason 3 O O
[type Reason 3 O O
2 Reason 3 O O
diabetes Reason 3 O O
mellitus](../diabetes-type-2) Reason 3 O O
are Reason 3 O O
eligible Reason 3 O O
for Reason 3 O O
the Reason 3 O O
study Reason 3 O O
3. Reason 3 O O
Subjects Reason 3 O O
with Reason 3 O O
eczema, Reason 3 O O
[psoriasis](../psoriasis), Reason 3 O O
lichen Reason 3 O O
simplex Reason 3 O O
chronicus, Reason 3 O O
or Reason 3 O O
(e.g., Reason 3 O O
patients Reason 3 O O
with Reason 3 O O
[psoriatic Reason 3 O O
arthritis](../arthritis) Reason 3 O O
are Reason 3 O O
excluded Reason 3 O O
from Reason 3 O O
the Reason 3 O O
study) Reason 3 O O
are Reason 3 O O
eligible Reason 3 O O
for Reason 3 O O
the Reason 3 O O
study Reason 3 O O
provided Reason 3 O O
all Reason 3 O O
of Reason 3 O O
the Reason 3 O O
following Reason 3 O O
conditions Reason 3 O O
are Reason 3 O O
met: Reason 3 O O
- Reason 3 O O
Rash Reason 3 O O
covers Reason 3 O O
< Reason 3 O O
10% Reason 3 O O
of Reason 3 O O
body Reason 3 O O
surface Reason 3 O O
area Reason 3 O O
- Reason 3 O O
Disease Reason 3 O O
is Reason 3 O O
well Reason 3 O O
controlled Reason 3 O O
at Reason 3 O O
baseline Reason 3 O O
and Reason 3 O O
requires Reason 3 O O
only Reason 3 O O
low-potency Reason 3 O O
topical Reason 3 O O
steroids Reason 3 O O
- Reason 3 O O
No Reason 3 O O
occurrence Reason 3 O O
of Reason 3 O O
acute Reason 3 O O
exacerbations Reason 3 O O
of Reason 3 O O
the Reason 3 O O
underlying Reason 3 O O
condition Reason 3 O O
requiring Reason 3 O O
psoralen Reason 3 O O
plus Reason 3 O O
ultraviolet Reason 3 O O
A Reason 3 O O
radiation, Reason 3 O O
methotrexate, Reason 3 O O
retinoids, Reason 3 O O
biologic Reason 3 O O
agents, Reason 3 O O
oral Reason 3 O O
calcineurin Reason 3 O O
inhibitors, Reason 3 O O
or Reason 3 O O
high-potency Reason 3 O O
or Reason 3 O O
oral Reason 3 O O
corticosteroids Reason 3 O O
within Reason 3 O O
the Reason 3 O O
previous Reason 3 O O
12 Reason 3 O O
months Reason 3 O O
7. O O O O
History O O O O
of O O O O
[idiopathic O O O O
pulmonary O O O O
fibrosis](../idiopathic-pulmonary-fibrosis), O O O O
active, O O O O
non-infectious O O O O
pneumonitis O O O O
requiring O O O O
corticosteroids. O O O O
8. Reason 1 O O
History Reason 1 O O
of Reason 1 O O
prior Reason 1 O O
positive Reason 1 O O
human Reason 1 O O
immunodeficiency Reason 1 O O
virus Reason 1 O O
(HIV) Reason 1 O O
test. Reason 1 O O
9. O O O O
Active O O O O
[hepatitis O O O O
B O O O O
virus](../hepatitis-b) O O O O
(HBV) O O O O
or O O O O
[hepatitis O O O O
C O O O O
virus](../hepatitis-c) O O O O
(HCV) O O O O
infection O O O O
(chronic O O O O
or O O O O
acute). O O O O
1. Reason 1 O O
Subjects Reason 1 O O
with Reason 1 O O
a Reason 1 O O
past Reason 1 O O
or Reason 1 O O
resolved Reason 1 O O
HBV Reason 1 O O
infection Reason 1 O O
are Reason 1 O O
eligible Reason 1 O O
for Reason 1 O O
this Reason 1 O O
study. Reason 1 O O
2. O O O O
HCV O O O O
positivity O O O O
is O O O O
defined O O O O
as O O O O
having O O O O
a O O O O
positive O O O O
HCV O O O O
antibody O O O O
test O O O O
followed O O O O
by O O O O
a O O O O
positive O O O O
HCV O O O O
ribonucleic O O O O
acid O O O O
(RNA) O O O O
test O O O O
at O O O O
screening; O O O O
the O O O O
HCV O O O O
RNA O O O O
test O O O O
will O O O O
only O O O O
be O O O O
performed O O O O
for O O O O
subjects O O O O
who O O O O
have O O O O
a O O O O
positive O O O O
HCV O O O O
antibody O O O O
test. O O O O
10. Reason 1 O O
Significant Reason 1 O O
[cardiovascular Reason 1 O O
disease](../cardiovascular-disease), Reason 1 O O
such Reason 1 O O
as Reason 1 O O
New Reason 1 O O
York Reason 1 O O
Heart Reason 1 O O
Association Reason 1 O O
class Reason 1 O O
III Reason 1 O O
or Reason 1 O O
greater Reason 1 O O
[cardiac Reason 1 O O
disease](../heart-disease), Reason 1 O O
[myocardial Reason 1 O O
infarction](../heart-attack), Reason 1 O O
or Reason 1 O O
[cerebrovascular Reason 1 O O
accident](../stroke) Reason 1 O O
within Reason 1 O O
3 Reason 1 O O
months Reason 1 O O
prior Reason 1 O O
to Reason 1 O O
initiation Reason 1 O O
of Reason 1 O O
study Reason 1 O O
treatment, Reason 1 O O
unstable Reason 1 O O
[arrhythmia](../cardiac-arrhythmia), Reason 1 O O
or Reason 1 O O
unstable Reason 1 O O
angina. Reason 1 O O
11. O O O O
Active O O O O
[chronic O O O O
obstructive O O O O
pulmonary O O O O
disease](../chronic-obstructive-pulmonary-disease) O O O O
(COPD) O O O O
requiring O O O O
use O O O O
of O O O O
home O O O O
oxygen O O O O
(O2) O O O O
or O O O O
systemic O O O O
steroid O O O O
therapy O O O O
> O O O O
10 O O O O
mg O O O O
prednisone O O O O
(or O O O O
equivalent) O O O O
daily. O O O O
12. Reason 1 O O
Asthma Reason 1 O O
requiring Reason 1 O O
systemic Reason 1 O O
corticosteroids Reason 1 O O
> Reason 1 O O
10 Reason 1 O O
mg Reason 1 O O
prednisone Reason 1 O O
(or Reason 1 O O
equivalent) Reason 1 O O
daily. Reason 1 O O
Inhaled Reason 1 O O
corticosteroids Reason 1 O O
for Reason 1 O O
the Reason 1 O O
treatment Reason 1 O O
of Reason 1 O O
asthma Reason 1 O O
are Reason 1 O O
permitted. Reason 1 O O
13. O O O O
Major O O O O
surgical O O O O
procedure O O O O
(including O O O O
joint O O O O
surgery) O O O O
other O O O O
than O O O O
for O O O O
diagnosis O O O O
within O O O O
4 O O O O
weeks O O O O
prior O O O O
to O O O O
initiation O O O O
of O O O O
study O O O O
treatment, O O O O
or O O O O
anticipation O O O O
of O O O O
need O O O O
for O O O O
a O O O O
major O O O O
surgical O O O O
procedure O O O O
during O O O O
the O O O O
course O O O O
of O O O O
the O O O O
study O O O O
a. Reason 1 O O
Placement Reason 1 O O
of Reason 1 O O
central Reason 1 O O
venous Reason 1 O O
access Reason 1 O O
catheter Reason 1 O O
(e.g., Reason 1 O O
port Reason 1 O O
or Reason 1 O O
similar) Reason 1 O O
is Reason 1 O O
not Reason 1 O O
considered Reason 1 O O
a Reason 1 O O
major Reason 1 O O
surgical Reason 1 O O
procedure Reason 1 O O
and Reason 1 O O
is Reason 1 O O
therefore Reason 1 O O
permitted. Reason 1 O O
14. O O O O
Severe O O O O
infection O O O O
within O O O O
4 O O O O
weeks O O O O
prior O O O O
to O O O O
initiation O O O O
of O O O O
study O O O O
treatment, O O O O
including, O O O O
but O O O O
not O O O O
limited O O O O
to, O O O O
hospitalization O O O O
for O O O O
complications O O O O
of O O O O
infection, O O O O
bacteremia, O O O O
or O O O O
severe O O O O
pneumonia. O O O O
15. Reason 1 O O
Any Reason 1 O O
other Reason 1 O O
disease, Reason 1 O O
metabolic Reason 1 O O
dysfunction, Reason 1 O O
physical Reason 1 O O
examination Reason 1 O O
finding, Reason 1 O O
or Reason 1 O O
clinical Reason 1 O O
laboratory Reason 1 O O
finding Reason 1 O O
that Reason 1 O O
contraindicates Reason 1 O O
the Reason 1 O O
use Reason 1 O O
of Reason 1 O O
an Reason 1 O O
investigational Reason 1 O O
drug, Reason 1 O O
may Reason 1 O O
affect Reason 1 O O
the Reason 1 O O
interpretation Reason 1 O O
of Reason 1 O O
the Reason 1 O O
results, Reason 1 O O
or Reason 1 O O
may Reason 1 O O
render Reason 1 O O
the Reason 1 O O
patient Reason 1 O O
at Reason 1 O O
high Reason 1 O O
risk Reason 1 O O
from Reason 1 O O
treatment Reason 1 O O
complications. Reason 1 O O
16. O O O O
Prior O O O O
allogeneic O O O O
stem O O O O
cell O O O O
or O O O O
solid O O O O
organ O O O O
transplantation. O O O O
17. Reason 3 O O
Treatment Reason 3 O O
with Reason 3 O O
a Reason 3 O O
live, Reason 3 O O
attenuated Reason 3 O O
vaccine Reason 3 O O
within Reason 3 O O
4 Reason 3 O O
weeks Reason 3 O O
prior Reason 3 O O
to Reason 3 O O
initiation Reason 3 O O
of Reason 3 O O
study Reason 3 O O
treatment, Reason 3 O O
or Reason 3 O O
anticipation Reason 3 O O
of Reason 3 O O
need Reason 3 O O
for Reason 3 O O
such Reason 3 O O
a Reason 3 O O
vaccine Reason 3 O O
during Reason 3 O O
the Reason 3 O O
course Reason 3 O O
of Reason 3 O O
the Reason 3 O O
study Reason 3 O O
or Reason 3 O O
within Reason 3 O O
5 Reason 3 O O
months Reason 3 O O
after Reason 3 O O
the Reason 3 O O
last Reason 3 O O
dose Reason 3 O O
of Reason 3 O O
atezolizumab. Reason 3 O O
Note: O O O O
Because O O O O
IL-6 O O O O
inhibition O O O O
may O O O O
interfere O O O O
with O O O O
the O O O O
normal O O O O
immune O O O O
response O O O O
to O O O O
new O O O O
antigen, O O O O
patients O O O O
should O O O O
be O O O O
brought O O O O
up O O O O
to O O O O
date O O O O
on O O O O
all O O O O
recommended O O O O
vaccinations, O O O O
except O O O O
for O O O O
live O O O O
vaccines, O O O O
prior O O O O
to O O O O
initiation O O O O
of O O O O
therapy O O O O
with O O O O
tocilizumab O O O O
to O O O O
maximize O O O O
vaccine O O O O
response. O O O O
18. O O O O
Treatment O O O O
with O O O O
investigational O O O O
therapy O O O O
within O O O O
28 O O O O
days O O O O
prior O O O O
to O O O O
initiation O O O O
of O O O O
study O O O O
treatment. O O O O
19. O O O O
Prior O O O O
treatment O O O O
with O O O O
adenosine-axis O O O O
inhibitors, O O O O
cluster O O O O
of O O O O
differentiation O O O O
137 O O O O
(CD137) O O O O
agonists O O O O
or O O O O
immune O O O O
checkpoint O O O O
blockade O O O O
therapies, O O O O
including O O O O
anti-cytotoxic O O O O
T-lymphocyte-associated O O O O
protein O O O O
4 O O O O
(CTLA-4), O O O O
ant-PD-1, O O O O
and O O O O
anti-PD-L1 O O O O
therapeutic O O O O
antibodies. O O O O
20. Reason 3 O O
Treatment Reason 3 O O
with Reason 3 O O
systemic Reason 3 O O
immunostimulatory Reason 3 O O
agents Reason 3 O O
[including, Reason 3 O O
but Reason 3 O O
not Reason 3 O O
limited Reason 3 O O
to, Reason 3 O O
interferon Reason 3 O O
and Reason 3 O O
interleukin Reason 3 O O
2 Reason 3 O O
(IL-2)] Reason 3 O O
within Reason 3 O O
4 Reason 3 O O
weeks Reason 3 O O
or Reason 3 O O
five Reason 3 O O
half-lives Reason 3 O O
of Reason 3 O O
the Reason 3 O O
drug Reason 3 O O
(whichever Reason 3 O O
is Reason 3 O O
longer) Reason 3 O O
prior Reason 3 O O
to Reason 3 O O
initiation Reason 3 O O
of Reason 3 O O
study Reason 3 O O
treatment. Reason 3 O O
21. Reason 1 O O
Treatment Reason 1 O O
with Reason 1 O O
systemic Reason 1 O O
immunosuppressive Reason 1 O O
medication Reason 1 O O
(including, Reason 1 O O
but Reason 1 O O
not Reason 1 O O
limited Reason 1 O O
to, Reason 1 O O
corticosteroids, Reason 1 O O
cyclophosphamide, Reason 1 O O
azathioprine, Reason 1 O O
methotrexate, Reason 1 O O
thalidomide, Reason 1 O O
and Reason 1 O O
anti-tumor Reason 1 O O
necrosis Reason 1 O O
factor Reason 1 O O
(TNF)- Reason 1 O O
agents) Reason 1 O O
within Reason 1 O O
2 Reason 1 O O
weeks Reason 1 O O
prior Reason 1 O O
to Reason 1 O O
initiation Reason 1 O O
of Reason 1 O O
study Reason 1 O O
treatment, Reason 1 O O
or Reason 1 O O
anticipation Reason 1 O O
of Reason 1 O O
need Reason 1 O O
for Reason 1 O O
systemic Reason 1 O O
immunosuppressive Reason 1 O O
medication Reason 1 O O
during Reason 1 O O
the Reason 1 O O
course Reason 1 O O
of Reason 1 O O
the Reason 1 O O
study, Reason 1 O O
with Reason 1 O O
the Reason 1 O O
following Reason 1 O O
exceptions: Reason 1 O O
1. Reason 1 O O
Patients Reason 1 O O
who Reason 1 O O
receive Reason 1 O O
acute, Reason 1 O O
low-dose Reason 1 O O
systemic Reason 1 O O
immunosuppressant Reason 1 O O
medication Reason 1 O O
or Reason 1 O O
a Reason 1 O O
one-time Reason 1 O O
pulse Reason 1 O O
dose Reason 1 O O
of Reason 1 O O
systemic Reason 1 O O
immunosuppressant Reason 1 O O
medication Reason 1 O O
(e.g., Reason 1 O O
48 Reason 1 O O
hours Reason 1 O O
of Reason 1 O O
corticosteroids Reason 1 O O
for Reason 1 O O
a Reason 1 O O
contrast Reason 1 O O
allergy) Reason 1 O O
are Reason 1 O O
eligible Reason 1 O O
for Reason 1 O O
the Reason 1 O O
study Reason 1 O O
2. O O O O
Patients O O O O
who O O O O
receive O O O O
mineralocorticoids O O O O
(e.g., O O O O
fludrocortisone), O O O O
corticosteroids O O O O
for O O O O
chronic O O O O
obstructive O O O O
pulmonary O O O O
disease O O O O
(COPD) O O O O
or O O O O
asthma O O O O
(=< O O O O
10 O O O O
mg O O O O
prednisone O O O O
or O O O O
insufficiency O O O O
(=< O O O O
10 O O O O
mg O O O O
prednisone O O O O
or O O O O
equivalent) O O O O
are O O O O
eligible O O O O
for O O O O
the O O O O
study. O O O O
22. Reason 1 O O
History Reason 1 O O
of Reason 1 O O
severe Reason 1 O O
allergic Reason 1 O O
anaphylactic Reason 1 O O
reactions Reason 1 O O
to Reason 1 O O
chimeric Reason 1 O O
or Reason 1 O O
humanized Reason 1 O O
antibodies Reason 1 O O
or Reason 1 O O
fusion Reason 1 O O
proteins. Reason 1 O O
23. Reason 1 O O
Known Reason 1 O O
hypersensitivity Reason 1 O O
to Reason 1 O O
Chinese Reason 1 O O
hamster Reason 1 O O
ovary Reason 1 O O
cell Reason 1 O O
products Reason 1 O O
or Reason 1 O O
to Reason 1 O O
any Reason 1 O O
component Reason 1 O O
of Reason 1 O O
the Reason 1 O O
atezolizumab Reason 1 O O
formulation. Reason 1 O O
24. Reason 1 O O
Known Reason 1 O O
allergy Reason 1 O O
or Reason 1 O O
hypersensitivity Reason 1 O O
to Reason 1 O O
any Reason 1 O O
of Reason 1 O O
the Reason 1 O O
study Reason 1 O O
drugs Reason 1 O O
of Reason 1 O O
their Reason 1 O O
excipients. Reason 1 O O
25. Reason 1 O O
Previous Reason 1 O O
treatment Reason 1 O O
with Reason 1 O O
any Reason 1 O O
cell-depleting Reason 1 O O
therapies, Reason 1 O O
including Reason 1 O O
investigational Reason 1 O O
agents Reason 1 O O
or Reason 1 O O
approved Reason 1 O O
therapies, Reason 1 O O
some Reason 1 O O
examples Reason 1 O O
include: Reason 1 O O
CAMPATH, Reason 1 O O
anti-cluster Reason 1 O O
of Reason 1 O O
differentiation Reason 1 O O
4 Reason 1 O O
(CD4), Reason 1 O O
anti-cluster Reason 1 O O
(CD5), Reason 1 O O
anti-cluster Reason 1 O O
of Reason 1 O O
differentiation Reason 1 O O
3 Reason 1 O O
(CD3), Reason 1 O O
anti-Cluster Reason 1 O O
of Reason 1 O O
Differentiation Reason 1 O O
19 Reason 1 O O
(CD19) Reason 1 O O
and Reason 1 O O
anti-Cluster Reason 1 O O
of Reason 1 O O
Differentiation Reason 1 O O
20 Reason 1 O O
(CD20). Reason 1 O O
26. Reason 1 O O
Treatment Reason 1 O O
with Reason 1 O O
intravenous Reason 1 O O
gamma Reason 1 O O
globulin, Reason 1 O O
plasmapheresis Reason 1 O O
or Reason 1 O O
Prosorba Reason 1 O O
column Reason 1 O O
within Reason 1 O O
6 Reason 1 O O
months Reason 1 O O
of Reason 1 O O
baseline. Reason 1 O O
27. Reason 1 O O
Previous Reason 1 O O
treatment Reason 1 O O
with Reason 1 O O
tocilizumab Reason 1 O O
(an Reason 1 O O
exception Reason 1 O O
to Reason 1 O O
this Reason 1 O O
criterion Reason 1 O O
may Reason 1 O O
be Reason 1 O O
granted Reason 1 O O
for Reason 1 O O
single Reason 1 O O
dose Reason 1 O O
exposure Reason 1 O O
upon Reason 1 O O
application Reason 1 O O
to Reason 1 O O
the Reason 1 O O
Sponsor-Investigator Reason 1 O O
on Reason 1 O O
a Reason 1 O O
case-by-case Reason 1 O O
basis). Reason 1 O O
28. Reason 1 O O
Any Reason 1 O O
previous Reason 1 O O
treatment Reason 1 O O
with Reason 1 O O
alkylating Reason 1 O O
agents Reason 1 O O
such Reason 1 O O
as Reason 1 O O
chlorambucil, Reason 1 O O
or Reason 1 O O
with Reason 1 O O
total Reason 1 O O
lymphoid Reason 1 O O
irradiation. Reason 1 O O
29. Reason 1 O O
History Reason 1 O O
of Reason 1 O O
severe Reason 1 O O
allergic Reason 1 O O
or Reason 1 O O
anaphylactic Reason 1 O O
reactions Reason 1 O O
to Reason 1 O O
human, Reason 1 O O
humanized Reason 1 O O
or Reason 1 O O
murine Reason 1 O O
[monoclonal Reason 1 O O
antibodies](../monoclonal-antibody). Reason 1 O O
30. Reason 1 O O
Evidence Reason 1 O O
of Reason 1 O O
serious Reason 1 O O
uncontrolled Reason 1 O O
concomitant, Reason 1 O O
nervous Reason 1 O O
system, Reason 1 O O
pulmonary, Reason 1 O O
renal, Reason 1 O O
hepatic, Reason 1 O O
endocrine Reason 1 O O
(include Reason 1 O O
uncontrolled Reason 1 O O
diabetes Reason 1 O O
mellitus) Reason 1 O O
or Reason 1 O O
gastrointestinal Reason 1 O O
disease Reason 1 O O
(including Reason 1 O O
complicated Reason 1 O O
diverticulitis, Reason 1 O O
[ulcerative Reason 1 O O
colitis](../ulcerative-colitis), Reason 1 O O
or Reason 1 O O
Crohn's Reason 1 O O
disease). Reason 1 O O
31. Reason 1 O O
Any Reason 1 O O
history Reason 1 O O
of Reason 1 O O
recent Reason 1 O O
serious Reason 1 O O
bacterial, Reason 1 O O
viral, Reason 1 O O
fungal, Reason 1 O O
or Reason 1 O O
other Reason 1 O O
opportunistic Reason 1 O O
infections. Reason 1 O O
32. Reason 1 O O
Primary Reason 1 O O
or Reason 1 O O
secondary Reason 1 O O
immunodeficiency Reason 1 O O
(history Reason 1 O O
of Reason 1 O O
or Reason 1 O O
currently Reason 1 O O
active) Reason 1 O O
unless Reason 1 O O
related Reason 1 O O
to Reason 1 O O
primary Reason 1 O O
disease Reason 1 O O
under Reason 1 O O
investigation. Reason 1 O O
33. Reason 1 O O
Any Reason 1 O O
medical Reason 1 O O
or Reason 1 O O
psychological Reason 1 O O
condition Reason 1 O O
that Reason 1 O O
in Reason 1 O O
the Reason 1 O O
opinion Reason 1 O O
of Reason 1 O O
the Reason 1 O O
principal Reason 1 O O
investigator Reason 1 O O
would Reason 1 O O
interfere Reason 1 O O
